California Poppy

Metadata

Approved Indications

Commission E (Germany)

• No Commission E monograph has been published for Eschscholzia californica

ESCOP

• No ESCOP monograph has been published for Eschscholzia californica

EMA/HMPC (European Medicines Agency)

• Status: Traditional Use
• Indications:
  • Relief of mild symptoms of mental stress
  • To aid sleep
• Monograph Reference: EMA/HMPC/680372/2013
• Population: Adults only
• Duration: If symptoms persist longer than 2 weeks during treatment, a doctor or a qualified healthcare practitioner should be consulted
• Basis: Long-standing traditional use (at least 30 years, including at least 15 years in the EU)

Agreement/Disagreement Between Bodies

• EMA alone: Only the EMA/HMPC has published a monograph; Commission E and ESCOP have not assessed California poppy
• Alignment with traditional use: The EMA indications align well with the documented traditional use of California poppy in Western herbalism as a mild sedative and anxiolytic
• Important distinction: The EMA monograph is based on traditional use, not on clinical trial evidence. The plausibility of the indications is supported by preclinical pharmacology (GABA-ergic activity) but not by dedicated human RCTs

Conditions Treated

Primary (Traditional Use — Limited Clinical Evidence)

• Mild anxiety and mental stress: EMA-approved traditional use indication; supported by preclinical evidence of anxiolytic activity
• Sleep disturbances (difficulty falling asleep): EMA-approved traditional use indication; supported by preclinical evidence of sedative activity

Secondary (Limited Evidence)

• Nervous restlessness in adults: Traditional use in Western herbalism, often in combination with valerian or passionflower
• Mild pain (traditional analgesic): Traditional use as a gentle analgesic, particularly for headaches and neuralgia; preclinical data supports mild analgesic properties

Traditional/Historical (Limited Evidence)

• Childhood restlessness and sleep difficulties (traditional use in French phytotherapy, though EMA monograph restricts to adults)
• Mild depressive mood (traditional; not supported by clinical data)
• Bedwetting in children (historical folk use; no modern evidence)
• Colic and spasmodic conditions (traditional antispasmodic use)
• Toothache (topical traditional use of fresh plant juice)

Mechanism of Action

Primary Mechanisms

GABA-A Receptor Modulation:

• Isoquinoline alkaloids, particularly californidine and eschscholtzine, modulate GABA-A receptors, enhancing inhibitory neurotransmission
• Alkaloid fractions have been shown to bind to benzodiazepine receptor sites on GABA-A receptors in vitro, producing sedative and anxiolytic effects similar in character (but much milder in potency) to benzodiazepine drugs
• This mechanism explains the traditional use for anxiety and insomnia without the addiction potential of benzodiazepines

Not an Opiate:

• Despite belonging to the Papaveraceae (poppy family), California poppy does not contain morphine, codeine, or any opiate alkaloids
• The alkaloid profile is entirely different from Papaver somniferum (opium poppy): California poppy contains benzophenanthridine and protopine-type alkaloids, not morphinan alkaloids
• This is a critical distinction for both safety and regulatory classification

Secondary Mechanisms

Distinction from Other Papaveraceae

• California poppy alkaloids act on GABAergic pathways, whereas opium poppy alkaloids act on opioid receptors
• The sedative mechanism is therefore fundamentally different: GABA-ergic sedation (similar to benzodiazepines or valerian) rather than opioid sedation
• No risk of opioid-type dependence or respiratory depression at any dose

Clinical Evidence Summary

Volume of Evidence

• Very limited. Clinical trial data for California poppy are extremely scarce. The EMA traditional use monograph is based on long-standing use and pharmacological plausibility rather than RCT evidence.

Key Studies

Anxiety

Sleep

• The EMA assessment report references observational data and traditional documentation supporting the use of California poppy for sleep disturbances, but no placebo-controlled RCT of California poppy monotherapy for insomnia was identified

Preclinical Evidence

• Rolland et al. 1991: Aqueous extracts of E. californica demonstrated sedative and anxiolytic properties in mice, including prolonged barbiturate-induced sleep and reduced anxiety in elevated plus-maze tests
• Gafner et al. 2006: Alkaloid fractions showed dose-dependent binding to GABA-A benzodiazepine receptor sites
• Multiple in vitro studies confirm GABA-A receptor modulation by californidine and eschscholtzine

Evidence Gaps

• No dedicated RCT of California poppy monotherapy for anxiety or insomnia
• The only RCT with clinical relevance used a combination product (with hawthorn and magnesium), making the individual contribution of California poppy impossible to assess
• No dose-response studies in humans
• No comparative studies with other sedative herbs (valerian, passionflower)
• No long-term safety data from clinical trials
• No studies in special populations (elderly, children)

European vs US/Anglophone Consensus

Safety Profile

Contraindications

• Known hypersensitivity to Eschscholzia californica or other Papaveraceae plants
• Pregnancy and lactation (see below)
• Children under 18 years (EMA recommendation; insufficient data)

Drug Interactions

• Benzodiazepines (diazepam, lorazepam, alprazolam): Theoretical additive sedation through shared GABA-A receptor mechanism; concurrent use should be approached with caution
• Other sedative/hypnotic drugs (zolpidem, zopiclone): Additive CNS depression possible
• Sedating antihistamines: Additive drowsiness
• Alcohol: Additive sedative effects; avoid excessive alcohol consumption during use
• MAO inhibitors: Theoretical interaction due to alkaloid content; limited data; use with caution
• No clinically documented drug interactions have been reported at standard therapeutic doses, but the theoretical interactions listed above are pharmacologically plausible

Side Effects

• Generally very well tolerated at recommended doses
• Mild nausea (rare)
• Drowsiness (dose-dependent; this is consistent with the intended sedative effect and should be considered when driving or operating machinery)
• No reports of dependence, tolerance, or withdrawal at standard doses
• No opiate-type effects (respiratory depression, euphoria, constipation) at any dose

Pregnancy/Lactation

• Pregnancy: Contraindicated. Insufficient safety data. The Papaveraceae family includes plants with uterotonic activity, and the alkaloid content presents a theoretical risk. Avoid during pregnancy
• Lactation: Contraindicated due to insufficient safety data and the presence of alkaloids that may transfer to breast milk
• Children: The EMA monograph restricts use to adults (18 years and over) due to insufficient data in pediatric populations. Despite traditional use in French phytotherapy for childhood sleep difficulties, no safety data supports pediatric use

Clinical Dosage

Standard Dosage Forms

EMA/HMPC Recommended Doses

• Herbal tea: 2 g per 150 mL boiling water, 1-2 times daily
• Dry extract: As per product-specific monograph recommendations
• Duration: If symptoms persist beyond 2 weeks of treatment, consult a healthcare practitioner
• Timing: For sleep disturbance, take 30-60 minutes before bedtime; for anxiety, doses may be distributed throughout the day

Clinical Trial Doses

• Hanus et al. 2004 (combination product): Fixed combination containing Eschscholzia californica dry extract (equivalent to 80 mg per tablet), taken 2 tablets morning and evening for 3 months
• No monotherapy clinical trial dose exists as a reference

Sources

• EMA/HMPC European Union Herbal Monograph on Eschscholzia californica Cham., herba (EMA/HMPC/680372/2013)
• EMA/HMPC Assessment Report on Eschscholzia californica Cham., herba (final assessment report)
• Hanus M, et al. Double-blind, randomised, placebo-controlled study to evaluate the efficacy and safety of a fixed combination containing two plant extracts (Crataegus oxyacantha and Eschscholzia californica) and magnesium in mild-to-moderate anxiety disorders. Curr Med Res Opin. 2004;20(1):63-71
• Rolland A, et al. Behavioural effects of the American traditional plant Eschscholzia californica: sedative and anxiolytic properties. Planta Med. 1991;57(3):212-216
• Gafner S, et al. Alkaloids from Eschscholzia californica and their capacity to inhibit binding of [3H]8-OH-DPAT to 5-HT1A receptors in vitro. J Nat Prod. 2006;69(3):432-435
• Schafer HL, et al. Sedative action of extract combinations of Eschscholtzia californica and Corydalis cava. Arzneimittelforschung. 1995;45(2):124-126
• Fedurco M, et al. Modulatory effects of Eschscholzia californica alkaloids on recombinant GABA-A receptors. Biochem Res Int. 2015;2015:617620
• American Botanical Council. Eschscholzia californica monograph. HerbalGram

Connections

• Compare with Passionflower as a fellow Western sedative herb with GABA-ergic activity and an EMA traditional use monograph; passionflower has somewhat more clinical evidence
• Compare with Valerian as the most established Western herbal sedative; valerian has Commission E, ESCOP, and EMA approval and significantly more clinical trial evidence for insomnia
• Related to Lavender (Silexan/Lasea) for anxiety; lavender has much stronger clinical evidence with well-powered RCTs for generalized anxiety disorder
• Compare with Hops as a mild sedative herb often combined with valerian; both have EMA traditional use status and limited standalone clinical evidence
• Compare with Kava for anxiolytic effects; kava has substantially stronger clinical evidence for anxiety but carries hepatotoxicity concerns that California poppy does not share
• The GABA-ergic mechanism of California poppy parallels that of Passionflower and Valerian, making them pharmacologically compatible for combination use